Transparent PBMs Help Keep Drug Costs Down

Share it

In a recent article in the Washington Times, the author blames PBMs for rising prescription drug costs, but does not take into account the measures that transparent, pass-through PBMs are taking.

We should be outraged about these rising costs – but not at PBMs. Outrage should be directed at the decision-makers who maintain the status quo even while knowing it is broken.

Almost every PBM contract is awarded and managed by a consultant. While three PBMs control 85% of the market, there are dozens of sophisticated, progressive alternatives that could be chosen – alternatives that do not tie revenue to the drug or to the pharmacy that dispenses it. These transparent PBMs do not have Wall Street or private equity influencing policy.

You don’t need the government to fix this problem. Just a good partner. Contact Araya to learn more.

See more news